Short answer
ArriVent BioPharma, Inc. (AVBP) filed an 8-K current report with the SEC on October 6, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Phase 3 FURVENT trial update for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC.
ArriVent BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 3 FURVENT trial update for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC
- Clinical update potentially material to firmonertinib’s development path and ArriVent’s valuation
- Press release dated October 6, 2026, contains the substantive trial details
Item 8.01 · Other Events
- Item 8.01 incorporates the Item 7.01 press release, excluding its second paragraph
- Investor significance depends on the underlying press release disclosure, not this incorporation reference
Item EX-99.1 · Exhibit EX-99.1
- FURVENT failed its primary BICR PFS endpoint, materially weakening firmonertinib’s first-line EGFR exon 20 insertion NSCLC approval case
- BICR median PFS: 11.0 months at 240mg vs 9.5 months control, p=0.0654, HR 0.75
- Confirmed BICR response rate: 60% at 240mg vs 33% control, but secondary benefits may not offset the failed primary endpoint
- Investigator-assessed PFS favored 240mg: 11.1 months vs 7.1 months control, HR 0.61
- Safety remained comparable, with Grade ≥3 treatment-related events at 26% for 240mg vs 40% control
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ArriVent BioPharma, Inc. 8-K filings
Get the next AVBP 8-K as it lands
Follow AVBP for push alerts, or ask the research agent what this filing means.